Belgium: Punching Well Above its Weight in Clinical Trials
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De…
Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on…
Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home…
Teun Grooters, co-founder and CEO of Arega – the exclusive distributor of Teva generics in Belgium – tells the story of the newly founded pharmaceutical company and shares his future…
Belgian Former Minister of Social Affairs, Public Health and Asylum & Migration Maggie de Block outlines some of the key reforms her Ministry has rolled out since she took office…
Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country…
Françoise Smets, dean of the Faculty of Medicine and Dentistry at Université Catholique de Louvain (UCLouvain), introduces the innovation and research capacity of the institution as the top-ranking French-speaking university…
Teva Pharma Belgium’s Eric Deschepper outlines how the global group’s restructuring has impacted its Belgian operations, its realignment from a pure generics to a specialty pharma player, and how the…
Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite…
See our Cookie Privacy Policy Here
